Meridian Bioscience to launch C. difficile GDH test in Europe

08/10/2011 | MedCityNews.com

Cinncinnati-based Meridian Bioscience has announced plans to release in Europe its ImmunoCard test designed to spot the GDH antigen, which is released by toxic and nontoxic strains of the Clostridium difficile bacterium. The test is targeted for use by laboratories to examine patients with diarrhea caused by C. difficile. The FDA cleared another Meridian test for the same antigen in May.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD